Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.
Satoshi NodaDaiki HiraRie OsakiTakehide FujimotoHiroya IidaSachiko Tanaka-MizunoAkira AndohMasaji TaniYoshito IkedaShin-Ya MoritaTomohiro TeradaPublished in: Cancer chemotherapy and pharmacology (2020)
From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC.
Keyphrases